Predictors for Remission in Rheumatoid Arthritis Patients: A Systematic Review

被引:128
|
作者
Katchamart, Wanruchada [1 ]
Johnson, Sindhu [2 ]
Lin, Hsing-Ju Lucy
Phumethum, Veerapong [3 ]
Salliot, Carine [4 ,5 ]
Bombardier, Claire [6 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Dept Med, Div Rheumatol, Bangkok 10700, Thailand
[2] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[3] Prapokklao Hosp, Chanthaburi, Thailand
[4] Paris Descartes Univ, Paris, France
[5] Cochin Hosp, AP HP, UPRES EA 4058, Paris, France
[6] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada
关键词
MODIFYING ANTIRHEUMATIC DRUG; RANDOMIZED CONTROLLED-TRIAL; MINIMAL DISEASE-ACTIVITY; BIOLOGICS-REGISTER; CLINICAL REMISSION; PROGNOSTIC-FACTORS; BRITISH-SOCIETY; OPEN-LABEL; METHOTREXATE; CRITERIA;
D O I
10.1002/acr.20188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To summarize the potential predictors of remission in patients with rheumatoid arthritis (RA). Methods. We performed a systematic review of prognostic studies that identified the predictors of remission in RA patients. Studies were identified in Medline, EMBase, and the Cochrane Registry, and by hand search. We included only studies performing multivariate analysis. Results. A total of 18 studies from 2,062 citations were included. The following variables were found to be the independent predictors of RA remission: male sex; young age; late-onset RA; short disease duration; nonsmoker; low baseline disease activity; mild functional impairment; low baseline radiographic damage; absence of rheumatoid factor and anti - citrullinated peptide; low serum level of acute-phase reactant, interleukin-2, and RANKL at baseline; MTHFR 677T alleles and 1298C alleles in the methotrexate (MTX) - treated patients; magnetization transfer ratio 2756A allele ± either the SLC 19A180A allele or the TYMS 3R-del6 haplotype in the MTX plus sulfasalazine combination - treated patients; early treatment with nonbiologic disease-modifying antirheumatic drug (DMARD) combinations; the use of anti - tumor necrosis factor (anti-TNF); the concurrent use of DMARDs in anti-TNF - treated patients; and moderate or good response to treatments at the first 6 months. The magnitude of the association in the individual predictor was diverse among the studies depending on the patient characteristics, the study characteristics, and the variables used to adjust for in the models. Conclusion. A number of independent predictors of remission, i.e., baseline clinical and laboratory characteristics and genetic markers, were summarized. The predictive value of prognostic factors recently identified needs to be confirmed. © 2010, American College of Rheumatology.
引用
收藏
页码:1128 / 1143
页数:16
相关论文
共 50 条
  • [41] REMISSION RATE OF TOCILIZUMAB IN CONTROLLED TRIALS AND OBSERVATIONAL STUDIES: SYSTEMATIC REVIEW OF RHEUMATOID ARTHRITIS
    Kucuksahin, O.
    Kilic, L.
    Aslar, Z.
    Bes, C.
    Yazisiz, V.
    Yazici, A.
    Solmaz, D.
    Kasifoglu, T.
    Kalyoncu, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1391 - 1391
  • [42] Achieving Clinical Remission for Patients With Rheumatoid Arthritis
    Aletaha, Daniel
    Smolen, Josef S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (05): : 457 - 458
  • [43] THE TREATMENT OF RHEUMATOID-ARTHRITIS PATIENTS IN REMISSION
    SOROKA, NF
    KLINICHESKAYA MEDITSINA, 1992, 70 (11-12): : 37 - 39
  • [44] Remission in Patients with rheumatoid Arthritis: Fewer Infections
    不详
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (06): : 449 - 449
  • [45] The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
    Curtis, Jeffrey R.
    Fox, Kathleen M.
    Xie, Fenglong
    Su, Yujie
    Collier, David
    Clinton, Cassie
    Oko-Osi, Hafiz
    RHEUMATOLOGY AND THERAPY, 2022, 9 (05) : 1329 - 1345
  • [46] The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
    Jeffrey R. Curtis
    Kathleen M. Fox
    Fenglong Xie
    Yujie Su
    David Collier
    Cassie Clinton
    Hafiz Oko-osi
    Rheumatology and Therapy, 2022, 9 : 1329 - 1345
  • [47] PREDICTORS OF LOW DISEASE ACTIVITY AND REMISSION AFTER ONE DOSE OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Dasgupta, B.
    Combe, B.
    Durez, P.
    Schulze-Koops, H.
    Louw, I.
    Wollenhaupt, J.
    Zerbini, C.
    Beaulieu, A.
    Yao, R.
    Huyck, S.
    Govoni, M.
    Weng, H. H.
    Vastesaeger, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 233 - 234
  • [48] Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry
    Gomez-Puerta, Jose A.
    Victoria Hernandez, M.
    Sanchez-Alonso, Fernando
    Yoshida, Kazuki
    Sanmarti, Raimon
    Solomon, Daniel H.
    Gomez-Reino, Juan J.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1097 - S1097
  • [49] PREDICTORS OF ACHIEVING STRINGENT REMISSION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS IN CLINICAL REMISSION FOLLOWING A TREAT-TO-TARGET STRATEGY
    Moller-Bisgaard, S.
    Georgiadis, S.
    Horslev-Petersen, K.
    Ejbjerg, B.
    Hetland, M. L.
    Ornbjerg, L.
    Glinatsi, D.
    Moller, J. Mollenbach
    Boesen, M.
    Stengaard-Pedersen, K.
    Madsen, O. Rintek
    Jensen, B.
    Villadsen, J.
    Hauge, E. M.
    Bennett, P.
    Hendricks, O.
    Asmussen, K.
    Kowalski, M.
    Lindegaard, M.
    Bliddal, H.
    Krogh, N. Steen
    Ellingsen, T.
    Nielsen, A.
    Balding, L.
    Jurik, A. G.
    Thomsen, H.
    Ostergaard, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1401 - 1401
  • [50] Predictors of Persistence of Power Doppler Ultrasound Synovitis in Rheumatoid Arthritis Patients in Clinical Remission.
    Filippi, Nathalie
    Lukas, Cedric
    Morel, Jacques
    Combe, Bernard
    Mouterde, Gael
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S51 - S52